Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

LUVERIS 450 UNIT / 0.72 ML — DIN 02339757

LUTROPIN ALFA : 450 UNIT / 0.72 ML · EMD SERONO, A DIVISION OF EMD INC., CANADA · SOLUTION · wholesale supply in Canada

Health Canada status: CANCELLED PRE MARKET

What is LUVERIS?

LUVERIS 450 UNIT / 0.72 ML contains LUTROPIN ALFA : 450 UNIT / 0.72 ML. It is listed in the Health Canada Drug Product Database under DIN 02339757, held by EMD SERONO, A DIVISION OF EMD INC., CANADA, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled pre market, status dated 26-Feb-2019. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label450 UNIT / 0.72 ML
Dosage formSOLUTION
RouteSUBCUTANEOUS

Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.

Substance and classification

Active substanceLutropin Alfa
ATC codeG03GA07
AHFS class68:18.00
Biosimilar biologicNo

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02339757
DIN (unpadded, as printed on some documents)2339757
Brand nameLUVERIS
Generic / active ingredientLUTROPIN ALFA : 450 UNIT / 0.72 ML
Market authorization holderEMD SERONO, A DIVISION OF EMD INC., CANADA
Health Canada schedulePrescription
ATC codeG03GA07
ATC anatomical main groupG — Genito-urinary system and sex hormones
ATC therapeutic subgroupG03GA
Current statusCANCELLED PRE MARKET
Status date26-Feb-2019
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

2 · Same class — other molecules in ATC G03GA

MoleculeCanadian brandsDINsMarketedSourceable
Follitropin AlfaGONAL-F · GONAL-F PEN103Yes
Follitropin DeltaREKOVELLE63Yes
CombinationsPERGOVERIS43Yes
Chorionic GonadotrophinA.P.L. - PWS-LIQ · APL INJ 1000 IU/ML · CHORIONIC GONADOTROPIN FOR INJECTION, USP · PREGNYL · +2 more62Yes
Choriogonadotropin AlfaOVIDREL22Yes
Follitropin BetaPUREGON · PUREGON (600 IU) · PUREGON 100 I.U. · PUREGON 50 I.U.61Yes
Human Menopausal GonadotrophinHUMEGON INJ 75 I.U. · MENOPUR · PERGONAL 75 I.U. · REPRONEX41Yes
UrofollitropinBRAVELLE · FERTINORM HP 150 - PWS DILUENT IM SC · FERTINORM HP 75 - PWS DILUENT IM SC · METRODIN 75 I.U.40Not in Canada
Lutropin AlfaLUVERIS10Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC G03G

ATC subgroupMoleculesDINsMarketed
G03GBClomifene40

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02339757. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.